|
|
 | | | |
- close
- close
- close
- close
| |||||||||
Isis Pharmaceuticals 8-K 2007 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT
REPORT Date of report (Date of earliest event reported): September 7, 2007 ISIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation)
1896 Rutherford Road Carlsbad, CA 92008 (Address of Principal Executive Offices and Zip Code) Registrant’s telephone number, including area code: (760) 931-9200 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events. On September 7, 2007, Isis Pharmaceuticals, Inc. (“Isis”) announced the launch of Regulus Therapeutics LLC, a joint venture with Alnylam Pharmaceuticals, Inc. focused on the discovery, development, and commercialization of microRNA (miRNA) therapeutics. A copy of the Press Release related to this announcement is attached hereto as Exhibit 99.1 and is incorporated herein by reference. This report includes forward-looking statements regarding the future therapeutic and commercial potential of Isis’ technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus. Any statement describing Isis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis’ goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. Isis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis’ programs are described in additional detail in Isis’ annual report on Form 10-K for the year ended December 31, 2006, and its quarterly report on Form 10-Q for the quarter ended June 30, 2007, which are on file with the SEC. Copies of this and other documents are available from the Company. Item 9.01. Financial Statements and Exhibits. (d) Exhibits.
2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
3 INDEX TO EXHIBITS
4 | ||||||||||||||||||||||||||||||||
| |||||||
